A phase 3 study assessing the efficacy, safety and tolerability of up to two 5-day treatment courses of tirbanibulin 1% ointment in patients with actinic keratosis (AK) over a treatment field up to approximately 100 cm&#178;

Klisyri (tirbanibulin ointment) - Almirall

tirbanibulin oral (KX-01 oral) - Athenex

https://eposters.aad.org/abstracts/72711

Julia Welzel; Jacek C Szepietowski; Carla Ferrándiz Pulido; Giovanni Pellacani; Klara Mosterd; Raquel Otero; Ana María Pérez Fierro; Lucio Malvisi; Hilary Siddall; Ignasi Pau-Charles; Thomas Dirschka

Mar 3, 2026